Novo Nordisk CEO explains decision to discontinue the long-acting insulin Levemir. He blamed pharmacy managers and health ...

and Elizabeth Warren, D-Mass., said the company's decision to discontinue Levemir, a long-acting insulin, "failed to take into consideration patient access to affordable, long-acting insulin ...

A patient advocacy group has started a campaign to stop Novo Nordisk from following through on a plan to stop making insulin product Levemir, arguing that it could leave some diabetics without an ...

The companies also hope to steal market share from Novo Nordisk, undercutting the long-acting Levemir (insulin detemir) by 21% and Tresiba (insulin degludec) an ultra long-acting insulin ...